Bladder cancer: can faster chemo before surgery boost cure rates?

NCT ID NCT07184021

Not yet recruiting Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests a dose-dense (faster) schedule of two chemotherapy drugs, gemcitabine and cisplatin, given before surgery for muscle-invasive bladder cancer. The goal is to see if this approach can completely eliminate the tumor in the bladder and lymph nodes. Thirty eligible patients will receive four cycles of the chemo regimen before undergoing bladder removal surgery, and researchers will measure how many achieve a complete pathological response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and cisplatin
What this could lead to: If successful, this could lead to a more effective chemotherapy regimen before bladder cancer surgery, potentially improving survival and reducing recurrence.
What could go wrong: This is a small, early-phase trial with only 30 participants. The intensive chemo schedule may cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder cancer Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER CANCER

Contacts and locations

Locations

Assiut university Hospital-Departement of clinical oncology.

Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.